<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice recommend that annual influenza vaccination can be considered in patients with established cardiovascular disease (class IIb, level C) [
 <xref ref-type="bibr" rid="CR38">38</xref>], based on the fact that the risk of a cardiovascular event (myocardial infarction or stroke) is more than four times higher after a respiratory tract infection, with the highest risk in the first 3Â days after infection [
 <xref ref-type="bibr" rid="CR39">39</xref>]. There have been developed several studies that demonstrate that influenza vaccination reduces mortality, hospitalization, and acute coronary syndromes in patients with coronary heart disease and/or heart failure [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
